Hong Kong’s Innovative Drug ETF (159567) fell 3.86% but saw active trading, with volume surpassing 2.5 billion yuan. The fund, which allows T+0 trading, has attracted steady inflows, including 55.35 million yuan in net financing on the 3rd and 45 million new shares added over the past month.
The divergence between price action and trading volume suggests mixed sentiment—while some investors may be taking profits, others appear to be accumulating positions. The ETF’s T+0 feature likely contributed to the heightened liquidity and intraday volatility.
Market participants will watch whether the recent capital inflows provide support or if the decline continues amid broader sector trends. The fund’s performance may hinge on upcoming biotech policy updates or breakthroughs in drug development pipelines.
Related topics:
